High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults

Does high-dose inactivated influenza vaccine (HD-IIV) provide additional protection against cardiovascular events in the general older population compared with standard-dose inactivated influenza vaccine (SD-IIV)?In this prespecified secondary analysis of the DANFLU-2 randomized clinical trial including 332 438 adults 65 years or older individually randomized to HD-IIV or SD-IIV, the incidence of cardiorespiratory hospitalization was 2.25% in the HD-IIV group and 2.38% in the SD-IIV group. The difference was driven primarily by a lower incidence of cardiovascular hospitalization (1.30% vs 1.40%).The results suggest additional effectiveness with HD-IIV compared with SD-IIV against cardiovascular outcomes but should be interpreted as exploratory findings in the setting of a large randomized clinical trial with a neutral primary outcome.

Corresponding Author: Tor Biering-Sørensen, MD, MSc, MPH, PhD, Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Gentofte Hospitalsvej 8, 3.th., 2900 Hellerup, Denmark (tor.biering@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.